TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer

doi:10.4251/wjgo.v11.i7.551

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8022)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

484

WORD

285

HTML

3903

Figures (1-2)

313

Tables (1-6)

286

Sum=5271

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

979

Download

1772

Sum=2751

Jul 15, 2019 (publication date) through Feb 11, 2025

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jul 15, 2019; 11(7): 551-566
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.551

Open in New Tab Full Size Figure Download Figure

Figure 1 Kaplan-Meier curves for disease free survival and overall survival according to thymidylate synthase polymorphisms: A: Disease free survival (DFS) according to 5’ untranslated region (UTR); B: Overall survival (OS) according to 5’UTR; C: DFS according to 3’UTR; D: OS according to 3’UTR. ^aP < 0.05 vs Group A and C; ^bP < 0.005. LOH: Loss of heterozygosity.

Open in New Tab Full Size Figure Download Figure

Figure 2 Kaplan-Meier survival curve for overall survival according to BRAF mutation status (V600E vs WT - wild type). ^aP < 0.05.

Citation: Ntavatzikos A, Spathis A, Patapis P, Machairas N, Vourli G, Peros G, Papadopoulos I, Panayiotides I, Koumarianou A. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer. World J Gastrointest Oncol 2019; 11(7): 551-566
URL: https://www.wjgnet.com/1948-5204/full/v11/i7/551.htm
DOI: https://dx.doi.org/10.4251/wjgo.v11.i7.551